Poster to be presented by research team from
University of Pittsburgh, led by
Jason Lohmueller, Ph.D., Assistant
Professor of Immunology
WEXFORD, Pa. , Oct. 4, 2023
/PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP)
("Coeptis" or "the Company"), a biopharmaceutical company
developing innovative cell therapy platforms for cancer, today
announced that an abstract involving SNAP-CAR has been accepted for
presentation at the Society for Immunotherapy of Cancer's
38th Annual Meeting (SITC 2023). SITC 2023 is
being held Nov. 1–5, 2023, at San
Diego Convention Center in San
Diego.
The poster presentation titled, "SNAP CAR T cells for
programmable antigen targeting," will detail research involving
SNAP-CAR, a "universal" CAR T cell therapy platform that can be
adapted to different cancer indications. Licensed by Coeptis
from the University of Pittsburgh,
SNAP-CAR offers an opportunity to direct the power of CAR T to an
array of cancers that have, until now, been inaccessible via
current cell therapy technologies by providing a highly
programmable antigen targeting platform.
"Having research on SNAP-CAR presented at such a renowned
oncology conference as SITC provides additional validation of the
technology's potential and the exceptional work being conducted by
Dr. Lohmueller and his team at the University
of Pittsburgh," said Dave
Mehalick, President and CEO of Coeptis Therapeutics.
"SNAP-CAR represents a powerful technology with the potential to be
engineered to address numerous cancers, including HER2-expressing
cancer, which we are targeting as our potential first-in-human
clinical development program."
About SNAP-CAR
SNAP-CAR, which Coeptis Therapeutics
licensed from the University of
Pittsburgh, is designed to be a "universal" CAR T cell
therapy platform that can be adapted to different cancer
indications. Instead of directly binding to a target on the tumor
cell, CAR T cells are co-administered with one or more antibody
adaptors that bind to the tumor cells and are fitted with a
chemical group that irreversibly connects them to the SNAP-CAR on
the therapeutic cells via a covalent bond. Pre-clinical studies in
mice have demonstrated that by targeting tumors via antibody
adaptor molecules, the SNAP-CAR therapy provides a highly
programmable therapeutic platform.
About Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings, Inc., together with its
subsidiaries including Coeptis Therapeutics,
Inc. and Coeptis Pharmaceuticals,
Inc., (collectively "Coeptis"), is a biopharmaceutical
company developing innovative cell therapy platforms for cancer
that have the potential to disrupt conventional treatment paradigms
and improve patient outcomes. Coeptis' product portfolio and rights
are highlighted by assets licensed from Deverra Therapeutics,
including an allogeneic cellular immunotherapy platform and DVX201,
a clinical-stage, unmodified natural killer cell therapy
technology. Additionally, Coeptis is developing a universal,
multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and the
GEAR™ cell therapy and companion diagnostic
platforms, which Coeptis is developing with VyGen-Bio and
leading medical researchers at the Karolinska Institutet.
Coeptis' business model is designed around maximizing the value of
its current product portfolio and rights through in-license
agreements, out-license agreements and co-development
relationships, as well as entering into strategic partnerships to
expand its product rights and offerings, specifically those
targeting cancer. The Company is headquartered in Wexford, PA.
For more information on Coeptis
visit https://coeptistx.com/.
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in
connection therewith contain or may contain "forward-looking
statements" (as defined in Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended). Forward-looking statements include statements
concerning our plans, objectives, goals, strategies, future events
or performance, and underlying assumptions, and other statements
that are other than statements of historical facts. When we use
words such as "may," "will," "intend," "should," "believe,"
"expect," "anticipate," "project," "estimate" or similar
expressions that do not relate solely to historical matters, we are
making forward-looking statements. Forward-looking statements are
not a guarantee of future performance and involve significant risks
and uncertainties that may cause the actual results to differ
materially and perhaps substantially from our expectations
discussed in the forward-looking statements. Factors that may cause
such differences include but are not limited to: (1) the inability
to maintain the listing of the Company's securities on the Nasdaq
Capital Market; (2) the risk that the integration of the Deverra
licensed assets will disrupt current plans and operations of the
Company; (3) the inability to recognize the anticipated benefits of
the newly-licensed assets, which may be affected by, among other
things, competition, the ability of the Company to grow and manage
growth economically and hire and retain key employees; (4) the
risks that the Company's products in development or the
newly-licensed assets fail clinical trials or are not approved by
the U.S. Food and Drug Administration or other applicable
regulatory authorities; (5) costs related to integrating the
newly-licensed Deverra assets and pursuing the contemplated asset
development paths; (6) changes in applicable laws or regulations;
(7) the possibility that the Company may be adversely affected by
other economic, business, and/or competitive factors; and (8) the
impact of the global COVID-19 pandemic on any of the foregoing
risks and other risks and uncertainties identified in the Company's
filings with the Securities and Exchange Commission (the "SEC").
The foregoing list of factors is not exclusive. All forward-looking
statements are subject to significant uncertainties and risks
including, but not limited, to those risks contained or to be
contained in reports and other filings filed by the Company with
the SEC. For these reasons, among others, investors are cautioned
not to place undue reliance upon any forward-looking statements in
this press release. Additional factors are discussed in the
Company's filings made or to be made with the SEC, which are
available for review at www.sec.gov. We undertake no obligation to
publicly revise these forward-looking statements to reflect events
or circumstances that arise after the date hereof unless required
by applicable laws, regulations, or rules.
CONTACTS
Coeptis Therapeutics, Inc.
Andy Galy, Sr. VP of Communications
andy.galy@coeptistx.com
Tiberend Strategic Advisors, Inc.
Investors
Daniel
Kontoh-Boateng
dboateng@tiberend.com
Media
David
Schemelia
dschemelia@tiberend.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-announces-research-involving-snap-car-accepted-for-presentation-at-the-society-for-immunotherapy-of-cancers-38th-annual-meeting-301946583.html
SOURCE Coeptis Therapeutics